Maxim Group Upgrades Cellectar Biosciences (CLRB) to Buy
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy upgraded Cellectar Biosciences (NASDAQ: CLRB) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
